Ticker

HOBOKEN, N.J.--(BUSINESS WIRE)--Wiley (NYSE: WLY), a global leader in authoritative content and research intelligence for the advancement of clinical practice, scientific discovery and learning, and OpenEvidence, the most widely used medical AI platform in the world, today announced a strategic partnership to bring Wiley's trusted scientific and medical content into OpenEvidence. Through the partnership, physicians…

HOBOKEN, N.J.--(BUSINESS WIRE)--Wiley (NYSE: WLY and WLYB), a global leader in authoritative content and research intelligence for the advancement of scientific discovery, innovation, and learning, will release its third quarter 2026 results prior to market open on Thursday March 5, 2026. The Company has scheduled a conference call beginning at 10am ET that day to discuss the results. Access webcast at Investor…

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does John Wiley & Sons (WLY) have what it takes?

John Wiley & Sons delivers solid margin improvement and research sales growth, aided by high-margin AI licensing revenues. WLY faces structural headwinds in its learning segment due to weak white-collar job markets and potential long-term enrollment declines from LLM disruption. Despite mixed segment performance, WLY maintains strong FCF generation, robust buybacks, and a combined yield near 13% after recent price…

HOBOKEN, N.J.--(BUSINESS WIRE)--Wiley to significantly expand the Advanced Portfolio into life, health, and social sciences disciplines, launching eight new journals in 2026.